arrow_back Back to App

Boosting US Drug Production: New Center for Biomanufacturing Excellence.

This law authorizes $120 million to establish a National Biopharmaceutical Center of Excellence aimed at accelerating the domestic production of advanced medicines. The goal is to secure the supply chain for critical drugs, reduce reliance on foreign manufacturers, and ensure faster access to innovative treatments for citizens. This initiative is expected to enhance health security and create specialized jobs.
Key points
Establishes a National Center of Excellence to research and scale up the manufacturing of biopharmaceuticals within the United States.
Strengthens domestic supply chains for critical medicines, reducing the risk of shortages and dependency on foreign sources.
Funds workforce training programs to develop skilled labor for the high-tech biotechnology and pharmaceutical sectors.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_6089
Sponsor: Rep. Houlahan, Chrissy [D-PA-6]
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Biomanufacturing Excellence Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_6089.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What are the main provisions?

Key points include:

  • Establishes a National Center of Excellence to research and scale up the manufacturing of biopharmaceuticals within the United States.
  • Strengthens domestic supply chains for critical medicines, reducing the risk of shortages and dependency on foreign sources.
  • Funds workforce training programs to develop skilled labor for the high-tech biotechnology and pharmaceutical sectors.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Houlahan, Chrissy [D-PA-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Science, Space, and Technology.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Public Investments Economy